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ABSTRACT
Purpose Use of RNA interference as novel therapeutic
strategy is hampered by inefficient delivery of its mediator,
siRNA, to target cells. Cationic polymers have been thoroughly
investigated for this purpose but often display unfavorable
characteristics for systemic administration, such as interactions
with serum and/or toxicity.
Methods We report the synthesis of a new PEGylated
polymer based on biodegradable poly(amido amine)s with
disulfide linkages in the backbone. Various amounts of
PEGylated polymers were mixed with their unPEGylated
counterparts prior to polyplex formation to alter PEG content
in the final complex.
Results PEGylation effectively decreased polyplex surface
charge, salt- or serum-induced aggregation and interaction with
erythrocytes. Increasing amount of PEG in formulation also
reduced its stability against heparin displacement, cellular uptake
and subsequent silencing efficiency. Yet, for polyplexes with high
PEG content, significant gene silencing efficacy was found, which
was combined with almost no toxicity.
Conclusions PEGylated poly(amido amine)s are promising
carriers for systemic siRNA delivery in vivo.
KEY WORDS biodegradable . delivery . PEGylation . poly
(amido amine)s . siRNA
INTRODUCTION
RNA interference (RNAi) using small interfering RNAs
(siRNAs) has emerged as a powerful tool for knockdown of
genes and holds great potential as a novel therapeutic
strategy for a broad range of diseases (1,2). The primary
limitation to clinical success, however, is the lack of efficient
delivery systems that can deliver siRNA to the target cell
population. siRNAs do not readily pass cellular membranes
due to their negative charge and are rapidly degraded by
serum nucleases.
Cationic polymers have widely been investigated for
siRNA delivery due to their great flexibility, ease of
manufacturing and modification possibilities (3). Typical
examples include poly(ethyleneimine) (pEI) (4), poly(L-
lysine) (pLL) (5), chitosan (6) and poly(2-(dimethyl-amino)
ethylmethacrylate) (pDMAEMA) (7). Although significant
progress has been made in improving these polymers for
siRNA delivery, either low efficiency and/or high cytotox-
icity remain to hinder their usefulness. Recently, we have
described a new class of biodegradable polymers based on
poly(amido amine)s with disulfide linkages in the backbone
(SS-PAA) that were specifically tailored for delivery of
siRNA (8,9). These copolymers were composed of N,N′-
cystaminebisacrylamide (CBA), 4-amino-1-butanol (ABOL)
and ethylene diamine (EDA) (p(CBA-ABOL/EDA)) and
were able to complex siRNA into positively charged
polyplexes that were efficiently taken up by cells and
induced target gene silencing. Moreover, this was combined
with low cellular toxicity, which encouraged us to perform
further functional studies.
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For cancer therapy, in order to reach distant tumors
or metastases, systemic administration of siRNA poly-
plexes is inevitable. Upon intravenous injection however,
positively charged polyplexes might potentially interact
aspecifically with serum proteins or erythrocytes and
other blood cells, leading to formation of aggregates,
which causes rapid clearance by the reticulo-endothelial
systems (RES) and sometimes significant toxicity (10).
The biocompatibility of polyplexes can be enhanced by
conjugation of poly(ethylene glycol) (PEG) to the
cationic polymer (PEGylation). Complexation of oligo-
nucleotides with PEG-containing copolymers leads to
the formation of particles with a core-shell structure, in
which the cationic polymer packs the oligonucleotide
within the particle core and the hydrophilic, non-
charged PEG chains form a shell layer around it (11).
In general, PEGylation of polyplexes results in a lower
surface charge, reduced interaction with blood compo-
nents, prolonged blood circulation and lower cytotoxicity
(12,13).On the other hand, steric shielding of the
polyplex particles also leads to reduced cellular associ-
ation and uptake, diminished endosomal escape proper-
ties, and inefficient siRNA release (14,15). These
contrasting effects associated with the use of PEG in
oligonucleotide delivery are also referred to as the ‘PEG
dilemma’ (16), and raise the need for strategies to fine-tune
the PEG content in polyplexes to optimize their physico-
chemical and biological properties. Recently, Brumbach et
al. demonstrated the feasibility of altering and optimizing
PEG content in polyplexes by formulating mixtures of a
polycation and its corresponding PEGylated counterpart
before complex formation, avoiding the need to synthesize
multiple copolymers with varying degrees of PEGylation to
identify optimal carrier candidates (17).
In this study we synthesized a new PEGylated polymer,
p(CBA-ABOL/EDA/PEG), based on the successful
p(CBA-ABOL/EDA) polymer and used mixtures of the
PEGylated and unPEGylated polymer in order to vary the
PEG content in the final polyplex. Polyplexes with different
PEG content were compared to corresponding unPEGy-
lated complexes regarding physicochemical characteristics,
stability, cellular uptake, gene silencing activity and in vitro
biocompatibility.
MATERIALS AND METHODS
Materials
All chemicals, 4-amino-1-butanol (ABOL, Merck), ethylene
diamine (EDA, Sigma-Aldrich), N,N′-cystaminebisacrylamide
(CBA, Polysciences) and α-amino-ω-hydroxy poly(ethylene
glycol) (PEG-NH2, 3000 g/mol, Iris Biotech GmbH) were
purchased in the highest purity and used without further
purification.
siRNAs
siRNAs were chemically synthesized and supplied by
Eurogentec (Maastricht, The Netherlands). Sequence of
siRNA against luciferase (siLuc) was 5′-GAU-UAU-GUC-
CGG-UUA-UGU-AUU-3′ (sense) and 5′-UAC-AUA-
ACC-GGA-CAU-AAU-CUU-3′ (antisense). For cellular
uptake studies, Alexa-488-modified siRNA was used (dye
was attached to the 5′-end of the sense strand).
Universal negative control siRNA (siNS) was purchased
from Eurogentec.
Polymer Synthesis and Characterization
Synthesis of p(CBA-ABOL/EDA) was performed as previ-
ously described (9). p(CBA-ABOL/EDA/PEG) was synthe-
sized by Michael addition polymerization of ABOL, EDA
and PEG-NH2 with N,N′-cystaminebisacrylamide (CBA).
Therefore, 424 mg (1.63 mmol) CBA, 98 mg (1.10 mmol)
ABOL and 500 mg (0.17 mmol) PEG-NH2 were dissolved
in methanol/water (4:1 v/v) and were allowed to react at
45°C in the dark in a nitrogen atmosphere. The reaction
mixture became homogeneous within 1 h. After 6 days of
prepolymerization, 22 mg (0.37 mmol) EDA was added
and the reaction was proceeded for another 2 days. Then
the polymerization was terminated by addition of a 10%
molar excess EDA, to consume remaining toxic acrylamide
endgroups. After termination, the reaction mixture was
diluted with hydrochloric acid (1 M) and water, purified by
ultrafiltration (MWCO 5000, pH 5) and recovered as its
HCl salt by lyophilization. 1H NMR (D2O) δ (ppm) = 1.58
(m, 2H, CH2CH2NR); 1.79 (m, 2H, CH2CH2OH); 2.69 (t,
4H, NHCH2CH2NH); 2.77 (t, 2H, CH2CONH); 2.83 (t,
4H, CH2SSCH2); 3.22 (t, 2H, CH2CH2NR); 3.32 (t, 2H,
COCH2CH2NH); 3.44 (t, 4H, CH2NRCH2); 3.51 (t, 4H,
NHCH2CH2SSCH2CH2NH); 3.60 (t, 2H, CH2OH); 3.65–
3.90 (m, 272H, OCH2CH2O). Polymers were character-
ized by 1H NMR (D2O), recorded on a Varian Innova
spectrometer (300 MHz). Molecular weights were deter-
mined by GPC relative to PEG standards, using a
GPCmax with an acetate buffer pH 4.5 containing 30%
(v/v) methanol as eluent.
Polyplex Formation
To prepare polyplexes at different polymer/siRNA (w/w)
ratios, appropriate amounts of polymer and siRNA were
each diluted in glucose-containing Hepes buffer (HBG:
20 mM Hepes, pH 7.4, 5 wt.% glucose). Next, polymer
solution was added to siRNA solution (4:1, v/v), followed
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by 5 s vortexing and 30 min incubation at room
temperature. To obtain polyplexes with different PEG
content, expressed as the weight percentage of PEG to total
polymer, polymer solutions of p(CBA-ABOL/EDA) and
p(CBA-ABOL/EDA/PEG) were mixed prior to polyplex
formation.
Polyplex Characterization
For gel retardation assays, polyplexes were prepared in 50 μl
HBG at a final siRNA concentration of 2.5 μMand incubated
for 1 h at 37°C in the presence or absence of 5 mM
glutathione. After addition of loading dye (Fermentas, St.
Leon-Rot, Germany), samples were run on a 4% agarose gel
containing 0.5 μg/ml ethidium bromide at 90 V for 10 min.
Hydrodynamic diameters and ζ-potentials were measured as
previously described (8).
Complex Aggregation in Salt
Polyplexes were prepared in 400 μl HBG at a final siRNA
concentration of 500 nM. Then, 2 ml PBS was added and
hydrodynamic diameters were measured at indicated time
points as described above.
Complex Aggregation in Serum
Polyplexes containing were prepared in 50 μl HBG at a
final siRNA concentration of 15 μM. 180 μl fetal bovine
serum (FBS) was added to 20 μl polyplex solution and
samples were incubated for 10 min at 37°C. Aggregation in
terms of turbidity increase of each sample was quantified by
absorbance detection at 595 nm.
Stability of Polyplexes Against Heparin
Polyplexes were prepared in 50 μl HBG at a final
siRNA concentration of 2.5 μM and incubated for
30 min with heparin solutions of different concentra-
tions, expressed as heparin/siRNA (w/w) ratio. After
addition of loading dye, samples were run on a 4%
agarose gel containing 0.5 μg/ml ethidium bromide at
90 V for 10 min.
Erythrocyte Aggregation and Hemolysis
Erythrocytes were obtained from 200 μl whole murine blood
by multiple centrifugation rounds (1000g, 10 min, 4°C)
followed by washing the pellet in PBS until the supernatant
was clear. The final pellet was resuspended in 4 ml PBS.
Subsequently, 160 μl erythrocyte suspension was added to
40 μl polyplex solution having a siRNA concentration of
4 μM and samples were incubated for 1 h at 37°C. Triton
X-100 (1%) in PBS (100% lysis) and HBG (0% lysis) were
used as controls. After a final centrifugation step, 150 μl of
the supernatant was analyzed for hemoglobin release by
absorbance detection at 550 nm. The pellet was resuspended
in 50 μl PBS for microscopic evaluation using a Nikon
TE2000-U microscope.
Cell Culture
H1299 (human lung cancer) cells stably expressing
firefly luciferase were cultivated at 37°C and 5% CO2
in RPMI 1640 (PAA laboratories GmbH, Pasching,
Austria) supplemented with 10% (v/v) FBS, 100 IU/ml
penicillin, 100 μg/ml streptomycin and 0.25 μg/ml
amphotericin B.
Cellular Uptake
Quantification of siRNA uptake was performed as previ-
ously described, with minor modifications (18). H1299 cells
were seeded in 6-well plates at a density of 1.6×105 cells
per well, 24 h before transfection. Cells were treated with
400 μl of different polyplexes containing Alexa-488 labeled
siRNA at a final siRNA concentration of 125 nM in FBS-
containing medium. After 4 h, cells were washed twice with
PBS to remove non-internalized polyplexes. 300 μl lysis
buffer (2% SDS, 1% Triton X-100 in PBS) was added to
lyse the cells and dissociate polyplexes. Cells were lysed for
1 h on ice, after which the lysates were centrifuged (14000g,
15 min, 4°C) to remove cell debris. 200 μl supernatant was
transferred to a black 96-well plate to measure fluorescence
using a Fluostar OPTIMA microplate-based multi-
detection reader (Isogen Life Science, Maarssen, The
Netherlands). The mean fluorescence intensity was normal-
ized to the amount of protein present in the sample,
determined using the MicroBCA™ protein assay (Pierce,
Rockford, USA).
For microscopy, cells were seeded in 12-well plates
on coverslips, 24 h before transfection. Cells were
treated with 20 μl of different polyplexes containing
Alexa-488 labeled siRNA at a final siRNA concentra-
tion of 125 nM. After 4 h, cells were washed with PBS
and fixed with 4% paraformaldehyde in PBS at room
temperature for 30 min. After fixation, slides were
washed, counterstained with DAPI and mounted using
Fluorsave (Calbiochem, San Diego, CA, USA). Cells
were imaged using a Nikon TE2000-U fluorescent
microscope (Nikon Benelux, Brussels, Belgium).
In Vitro Gene Silencing
H1299 cells were seeded in 96-well plates at a density of
8000 cells per well, 24 h before transfection. Cells were
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treated with 20 μl of different polyplexes at a final
siRNA concentration of 125 nM in FBS-containing
medium. After 4 h, medium was replaced, and cells
were incubated for another 48 h. Then, cells were
washed and lysed in 100 μl reporter gene lysis buffer
(Promega, Leiden, The Netherlands). After a freeze/
thaw cycle, 50 μl lysate was mixed with 50 μl luciferase assay
reagent (Promega) and luciferase activity was determined by
measuring the luminescence for 10 s at room temperature
using a Fluostar OPTIMA microplate-based multi-detection
reader equipped with a microinjector (Isogen Life Science).
Luciferase activity of untreated cells was defined as 100%
expression.
Statistical Analysis
Results were analyzed using Student’s t-tests to assess
statistical significances. For multiple comparisons, ANOVA
with a Bonferroni post-test was used.
RESULTS AND DISCUSSION
Polymer Synthesis
Two reducible poly(amido amine) copolymers were synthe-
sized by Michael-type addition polymerization from N,N′-
cystaminebisacrylamide (CBA), 4-amino-1-butanol (ABOL)
and ethylene diamine (EDA) with or without α-amino-ω-
hydroxy poly(ethylene glycol) (PEG-NH2), to obtain a
PEGylated and a non-PEGylated polymer (Fig. 1). All
polymers were obtained as a white to slightly yellow brittle
material. The molar ratio between ABOL and EDA was
found to be optimal at 75/25 for the unPEGylated polymer
(9) and this ratio was used again here. The characteristics of
the final polymers are listed in Table 1. The obtained ratio
between ABOL, EDA and PEG, as well as the PEG
content were determined from the NMR spectra. Molecu-
lar weights were determined by GPC. The obtained ratio
between ABOL/EDA in the polymers deviated only slightly
from the feed ratio and the obtained PEG fraction in the
PEGylated polymer corresponded well with the aimed
fraction. Based on the previous results in the p(CBA-
ABOL/EDA) synthesis (9), all polymers are expected to be
linear.
Polyplex Characteristics
In order to prepare polyplexes with various amounts of
PEG in the formulations, mixtures containing different
ratios of p(CBA-ABOL/EDA) and p(CBA-ABOL/EDA/
PEG) were taken and mixed with siRNA. As it has
previously been shown that PEG conjugation to polymeric
vectors can interfere with polyplex formation and siRNA
complexation, we first investigated the physicochemical
properties of polyplexes with different PEG contents.
To determine the ability of the polymer mixtures to
complexate siRNA, an agarose gel retardation assay was
performed. Polyplexes were formed at polymer/siRNA
(w/w) ratios of 0 (free siRNA), 3, 6, 12, 24 and 48. In
the determination of the w/w ratios, the weight of PEG
was not taken into account, thus the given ratios reflect
the relative amount of cationic polymer in each
formulation. For unPEGylated polyplexes, total siRNA
retardation was observed at w/w ratios 12 and higher,
indicating that the nucleic acid remained associated with
the cationic polymers that do not migrate into the gel
(Fig. 2a, left). Complete retardation at this w/w ratio was
also observed for polyplexes with 15, 30 and 45 wt.% PEG
(Fig. 2b–d, left). For polyplexes that were prepared with
45 wt.% PEG at the lower w/w ratios 3 and 6, siRNA was
still visible in the wells, indicating that it was bound to the
polymer but not completely shielded as ethidium bromide
was still able to intercalate (Fig. 2d, left).
The disulfide bridges in the poly(CBA-ABOL/EDA)
polymers are expected to be cleaved in the cytosol because
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Fig. 1 Schematic representation of the synthesis of the p(CBA-ABOL/EDA) and p(CBA-ABOL/EDA/PEG) copolymers.
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of its high redox potential as compared to the extracellular
environment. To investigate whether the accessibility of
these disulfide bonds for reducing agents like glutathione is
restricted by PEGylation of the polyplexes, polyplexes were
incubated for 1 h at 37°C in the presence of 5 mM
glutathione and subjected to electrophoresis. For all
formulations, this incubation resulted in total release of
siRNA from the polyplexes, indicating that the PEG chains
do not interfere with polymer reduction (Fig. 2a–d, right).
Based on these results, further studies were performed with
polyplexes prepared at polymer/siRNA w/w ratio 24.
The influence of PEGylation on polyplex size and
surface charge was investigated using dynamic light
scattering and laser Doppler electrophoresis, respectively.
UnPEGylated polyplexes prepared at w/w ratio 24 were
around 160 nm in diameter and positively charged (± 20 mV)
(Fig. 3a, b). Polyplexes with 15 wt.% or 30 wt.% PEG were
around the same size, while polyplexes formed with 45 wt.%
PEG were slightly smaller (Fig. 3a). Smaller sizes for
PEGylated polyplexes as compared to their unPEGylated
counterparts has been shown before and was contributed to
effective shielding and subsequent abolished aggregation
(19,20). Increased size for PEGylated polyplexes has also
been reported, but always linked to perturbed nucleic acid
condensation (17,21). However, together with the data
obtained from the agarose gel retardation assay, these
results show that PEG conjugation of these polymers
does not negatively affect polyplex formation. Further-
more, PEGylation substantially decreased polyplex sur-
face charge down to ±5 mV for polyplexes with 45 wt.%
PEG, which is in accordance with other reports on effects of
polyplex PEGylation (17,22,23) (Fig. 3b).
Table 1 Synthesis Characteristics
Polymer Feed compositiona
ABOL/EDA/PEG
Obtained compositionb
ABOL/EDA/PEG
Wt % PEGc Mw (kg/mol) PDI Mw PAA (kg/mol)
d
p(CBA-ABOL/EDA) 75 / 25 / 0 80 / 20 / 0 0% 11.6 2.4 11.6
p(CBA-ABOL/EDA/PEG) 67 / 23 / 10 59 / 31 / 10 52% 47.8 1.4 23.9
a Stoichiometrical feed ratio of monomers
b Determined by 1H NMR
c PEG fraction of the polymer expressed as a weight percentage
dMolecular weight of the PAA fraction in the polymer, calculated from the wt.% PEG
Fig. 2 Agarose gel retardation of polyplexes prepared at w/w ratios 0
(siRNA only) to 48, after 1 h incubation at 37°C in the absence or
presence of 5 mM glutathione. Polyplexes were prepared using polymers
without PEG (a) or with a PEG content of 15 wt.% (b), 30 wt.% (c) and
45 wt.% (d).
Fig. 3 Size (a) and ζ-potential (b) of polyplexes prepared at polymer/
siRNA (w/w) ratio 24 using polymers with increasing PEG content, as
determined by dynamic light scattering and laser Doppler electrophoresis.
Results are shown as mean ± SD for three individual measurements.
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Polyplex Stability
Systemic administration exposes polyplexes to physiological
ionic strengths and anionically charged proteins, which can
induce aggregation and destabilization by non-specific
interactions (13). To investigate whether PEGylation
prevents polyplex aggregation at physiological salt concen-
trations, pre-formed polyplexes were incubated in PBS and
size measurements were performed over time using
dynamic light scattering. As expected, polyplexes without
PEG showed a gradual increase in size to approximately
800 nm after 4 h due to aggregation (Fig. 4). Increasing the
PEG content resulted in enhanced stabilization of the
polyplexes. Polyplexes containing 15 wt.% PEG displayed
an aggregation profile similar to that of polyplexes without
PEG, whereas a content of 30 wt.% PEG substantially
inhibited aggregation. 45 wt.% PEG totally prevented
aggregation up to 4 h. Similar PEG-density dependent
stabilization profiles were found for post-PEGylated
cyclodextrin-based polyplexes formed with siRNA (24) or
pDNA (25). Next, we assessed effects of PEGylation on
serum-induced aggregation by incubating pre-formed poly-
plexes in 90% FCS. Aggregation in terms of turbidity
increase was significantly prevented by coupling of PEG to
the polymeric structures and appeared to be more pro-
nounced with increasing PEG content (Fig. 5). Combined,
these results indicate that PEGylation prevents polyplex
aggregation in biological media. Serum proteins as well as
extracellular matrix components can however, besides
inducing aggregation, also lead to vector disassembly (26).
To evaluate possible effects of PEG on polyplex stability
against competing anions, we tested the susceptibility of our
polyplexes to heparin displacement. Heparin is one of the
glycosaminoglycans (GAG), which are negatively charged
polysaccharides that are the major components of the
extracellular matrix in many tissues and are also found on
the cell surface (27). Polyplexes with different PEG contents
were prepared and subsequently incubated with increasing
heparin concentrations. Polyplex dissociation in terms of
siRNA release was shown by electrophoresis of the samples
on an ethidium bromide-containing agarose gel (Fig. 6). For
unPEGylated polyplexes, dissociation occurred at hepa-
rin/siRNA (w/w) ratio 4 and higher. The presence of
15 wt.% PEG did not alter the stability against heparin,
but for polyplexes with higher PEG content a slightly
decreased resistance against heparin competition was
observed. Such a negative effect of PEG on polyplex
stability was reported earlier for pEI-PEG/siRNA
polyplexes and contributed to the weakened interaction
with siRNA in the case of the PEGylated polymer as a
result of decreased charge density (23).
Fig. 4 Polyplex stability in a physiological salt solution. Polyplexes were
prepared at polymer/siRNA (w/w) ratio 24 using polymers with increasing
PEG content. Particle sizes were determined by dynamic light scattering.
Results are shown as mean ± SD for two individual measurements.
Fig. 5 Serum-induced aggregation of polyplexes. Polyplexes were prepared
at polymer/siRNA (w/w) ratio 24 using polymers with increasing PEG content.
Aggregation in 90% FCS in terms of turbidity increase was quantified by
absorbance detection at 595 nm. Results are shown as mean± SD for n=3.
Statistically significant differences versus polyplexes without PEG are denoted
by *** (p<0.001).
Fig. 6 Heparin displacement assay. Polyplexes were prepared at w/w ratio
24 and incubated for 30 min at 37°C in the presence of increasing amounts of
heparin, expressed as heparin/siRNA (w/w) ratio. Polyplexes were prepared
using polymers without PEG (a) or with a PEG content of 15 wt.% (b),
30 wt.% (c) and 45 wt.% (d).
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Erythrocyte Aggregation and Hemolysis
Besides interactions with salt, proteins and/or the extracel-
lular matrix, interactions with blood cells such as eryth-
rocytes occur after systemic injection. Erythrocytes bear a
negative surface charge and are known to interact with
positively charged polyplexes, leading to aggregate forma-
tion and systemic toxicity (28). To evaluate the influence of
PEG on polyplex-induced erythrocyte aggregation and
hemolysis, polyplexes with different PEG content were
incubated for 1 h with freshly purified red blood cells.
Erythrocytes were pelleted and visualized under a micro-
scope, while the supernatant was used for measuring the
degree of hemolysis as determined by absorbance detection
at 550 nm. Control polyplexes were prepared using poly(2-
(dimethylamino)ethyl methacrylate) (pDMAEMA), which
were previously shown to induce severe erythrocyte
aggregation (29). In our experiments, erythrocytes incu-
bated with pDMAEMA polyplexes also displayed obvious
aggregation as compared to cells incubated with buffer
only. Polyplexes prepared from p(CBA-ABOL/EDA)
polymers induced only mild aggregation, which was even
further decreased using PEGylated polymers. For poly-
plexes containing 30 or 45 wt.% PEG, no erythrocyte
aggregation was observed (Fig. 7a). A similar trend was
observed for the degree of hemolysis. For polyplexes
formed with pDMAEMA, approximately 16% hemolysis
was observed, similar to what others have found for pEI
polyplexes (30). A much lower hemolytic activity was
measured for pCBA-ABOL/EDA polyplexes (approx.
4%). For PEGylated polyplexes, even less hemolysis was
observed, down to less than 1% hemolysis for polyplexes
with 45 wt.% PEG (Fig. 7b). Together, these data indicate
that PEGylated polymers have reduced interactions with
blood components, which is in accordance with findings
from others (13,31).
Cellular Uptake and Gene Silencing
To study the effects of PEGylation on intracellular uptake
of polyplexes, H1299 cells were transfected with polyplexes
with increasing PEG content, formulated using Alexa488-
labeled siRNA. For quantification of siRNA internalization,
fluorescence was determined in cell lysates 4 h after
transfection. 2% SDS was added to the lysis buffer to
ensure complete polyplex dissociation, preventing possible
quenching effects (18). As shown in Fig. 8a, for all polymers,
uptake was less than for control lipoplexes based on
Lipofectamine 2000. Cellular uptake decreased with increas-
ing PEG content in the polyplex. While the extent of uptake
for polyplexes with 15 wt.% PEG was similar to that of
unPEGylated polyplex, uptake was significantly reduced for
polyplexes containing 30 wt.% PEG and almost completely
inhibited for polyplexes containing 45 wt.% PEG. Lower
cellular uptake of polyplexes having increased PEG content
was also confirmed by fluorescent microscopy (Fig. 8b). As
suggested by others, cellular uptake for PEGylated poly-
plexes is reduced because of PEG stealth effects, causing
strongly reduced interaction with the cellular membrane
(32,33).
Fig. 7 Polyplex-induced erythrocyte aggregation and hemolysis. Polyplexes
were prepared using polymers with increasing PEG content and incubated
with erythrocytes for 1 h at 37°C. pDMAEMA polyplexes were used as
controls. (a) Microscopic image of erythrocyte aggregation. Aggregates are
indicated with arrows. (1) HBG (2) pDMAEMA (3–6) p(CBA-ABOL/EDA)
with increasing PEG content. (b) Degree of hemolysis as determined by
absorbance detection at 550 nm. Results are shown as mean ± SD
for n=3. Statistically significant differences versus polyplexes without
PEG are denoted by ** (p<0.01) or *** (p<0.001).
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Gene silencing potential of the PEGylated polyplexes
was evaluated using H1299 cells that stably express the
luciferase enzyme. As PEGylation reduced cellular
uptake and hence is likely to reduce silencing efficiency,
cells were transfected using a rather high siRNA
concentration of 125 nM. At this concentration, trans-
fection with Lipofectamine 2000 lipoplexes resulted in
almost complete luciferase silencing. UnPEGylated poly-
plexes could efficiently inhibit luciferase expression,
however this was combined with a relatively high
cytotoxicity (approximately 50%), as indicated by the
reduced luciferase expression of cells treated with
control siRNA (Fig. 9). The apparent toxicity of these
polyplexes was not observed before (8,9), and is likely
caused by the increased polymer and siRNA dose which
may lead in the presence of serum to particle aggregation
and precipitation. As expected, with increasing PEG
content, silencing efficiency was reduced, as well as
cytotoxicity. In contrast, others have shown that PEGyla-
tion of pEI polyplexes leads to enhanced silencing activity,
due to decreased polyplex stability and more efficient
siRNA release (23). For our systems, siRNA release from
the complex is most likely not a limiting factor for their
biological activity, as a result of the triggered release
mechanism due to the cleavage of the disulfide linkages in
the polymer backbone. Interestingly, for polyplexes with
high PEG content (30 or 45 wt.%) cell viability was
unaffected, while significant luciferase knockdown was still
observed. Although the knockdown efficacy of PEGylated
polyplexes in vitro is low as compared to Lipofectamine
2000 or unPEGylated polymers, improved in vivo delivery
due to decreased aggregation and increased circulation
time can be expected. Addition of targeting ligands to the
distal ends of the PEG chains can be expected to boost
their cellular uptake, resulting in increased silencing
efficiency, and this is considered as the next step in the
development of targeted delivery systems for siRNA (34).
CONCLUSIONS
In this study, the synthesis of a novel PEGylated polymer
based on biodegradable poly(amido amine)s with disulfide
linkages in the backbone was described for the delivery of
siRNA. Polyplexes with various PEG contents were
prepared by mixing the PEGylated polymer with its
unPEGylated counterpart prior to polyplex formation.
PEGylation decreased polyplex surface charge, increased
their stability against salt and serum and decreased polyplex
interactions with erythrocytes. Controversially, PEGylated
polyplexes showed decreased resistance against heparin
displacement. Cellular uptake was lower for polyplexes with
increasing PEG content, which resulted in reduced gene
silencing efficiency, but also reduced toxicity. Polyplexes
with PEG contents of 30 and 45 wt.% showed significant
silencing efficiency in the absence of toxicity, which makes
Fig. 8 Cellular uptake of PEGylated polyplexes. (a) Mean fluorescence
intensity (MFI) of H1299 cells determined 4 h after transfection, corrected
for protein content. Polyplexes were prepared using polymers with
increasing PEG content and fluorescently labeled siRNA. Lipofectamine
2000 was used as control. Results are shown as mean ± SD for n=2–3.
Statistically significant differences versus polyplexes without PEG are
denoted by * (p<0.05) or *** (p<0.001). (b) Fluorescent microscopy
pictures of H1299 treated cells. Nuclei are stained blue (DAPI), siRNA
appears as green (Alexa-488).
Fig. 9 Gene silencing activity of PEGylated polyplexes. Luciferase expression
of H1299 cells was determined 48 h after transfection. Polyplexes were
prepared using polymers with increasing PEG content and luciferase siRNA
(black bars) or non-silencing control siRNA (white bars). Lipofectamine 2000
was used as control. Results are shown as mean ± SD for n=3. Statistically
significant differences of luciferase siRNA versus non-silencing control siRNA
are denoted by ** (p<0.01) or *** (p<0.001).
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them promising carriers for delivery of siRNA in vivo. The
addition of targeting ligands on the PEG chain ends is
expected to further improve their cellular uptake and
silencing potential.
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